Aton (Hybrigenics) announced on Friday evening that it had postponed its sales target of 60 million euros by 2025 "to a later financial year", which caused its share price to fall on the Paris stock exchange.

The medical science specialist explained that it had deemed it reasonable to postpone its financial targets in view of current economic conditions and difficulties in raising funds.

Although it has initiated several discussions with investment funds, the Group explains that the completion of these transactions remains uncertain, which rules out, for the time being, the scenario of accelerating the development of its subsidiaries.

As far as 2024 is concerned, Aton says it is aiming for business growth, albeit at a slower pace than expected, and which should not enable it to break even.

Following all these announcements, the share price fell by more than 27% on Monday on the Paris Bourse.

Copyright (c) 2023 All rights reserved.